INTRODUCTION {#s1}
============

T-cell acute lymphoblastic leukemia (T-ALL) accounts for approximately 15% and 25% of ALL in pediatric and adult patients, respectively \[[@R1]\], and is clinically characterized as a high-risk malignancy with a relapse rate of approximately 30% \[[@R2]\]. This disease is commonly correlated with acquired chromosomal translocations and other genetic or epigenetic abnormalities, leading to aberrant expression of a series of transcription factors \[[@R3]\]. Most of the chromosome rearrangements involve NOTCH1, which is constitutively active because of t (7;9) (q34:q34.3) activating mutations, also known as Notch homolog 1 and translocation-associated Drosophila, human genes encoding single-pass transmembrane receptor. Mutations in the NOTCH1 gene are the most common genetic abnormalities found in T-ALL, affecting more than 50% of patients \[[@R4], [@R5]\]. Mutations affect two domains---the extracellular heterodimerization domain (HD), where mutations lead to ligand-independent cleavage, and the C-terminal proline, glutamic acid, serine, and threonine (PEST)--rich domain truncating mutations \[[@R6]\]. Weng et al. \[[@R3]\] demonstrated activation of NOTCH1 mutations in more than 50% of pediatric T-ALL patients. Aberrant NOTCH1 signaling was originally linked to the pathogenesis of T-ALL by the cloning of the t (7;9) (q34; q34.3) chromosomal translocation, which leads to the expression of a truncated and constitutively active form of NOTCH1. The γ-secretase inhibitors (GSIs), which block the proteolytic cleavage of the NOTCH receptors and suppress the release of activated NOTCH1 (ICN1) from the membrane, have been proposed as a potential therapy in T-ALL. Moreover, F-box and WD-40 domain protein 7 (FBXW7) promotes proteasome degradation in activated NOTCH1. FBXW7 is an E3 ubiquitin ligase that recognizes the PEST domain of ICN1 and accelerates the termination of NOTCH1 signaling in the nucleus \[[@R7]\]. Hence, NOTCH1 mutations, FBXW7 mutations, or both lead to activation of the NOTCH1 pathway \[[@R8]\]. Studies have examined the correlation between NOTCH1/FBXW7 status and T-ALL. However, the outcome and results are inconsistent \[[@R9]--[@R19]\], and the impact of NOTCH1/FBXW7 mutations on long-term outcome in T-ALL patients is still undetermined \[[@R20]\].

In this meta-analysis, we investigated the relevance of NOTCH1 mutations, FBXW7 mutations, or both in relation to long-term prognosis.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

Trials were classified into three subgroups, NOTCH1 alone, FBXW7 alone, and NOTCH1/FBXW7, because NOTCH1 and FBXW7 belong to the same signaling pathway. In each group, children and adults were analyzed. Patients younger than 18 years were assigned to the child group. Patients older than 18 years were assigned to the adult group. Overall survival (OS) was defined as the time from diagnosis to death by any cause or to last follow-up. Event-free survival (EFS) was defined as the time from diagnosis to the date of last follow-up in complete remission or first event. Events were resistance to therapy (non-response), relapse, secondary neoplasm or death by any cause. Failure to achieve remission because of early death or non-response was considered an event at time zero.

NOTCH1 and FBXW7 mutations {#s2_2}
--------------------------

A total of 866 patients were screened for both NOTCH1 and FBXW7 mutations in 12 trials \[[@R9]--[@R19], [@R21]\]. Details are shown in Table [1](#T1){ref-type="table"}. Based on age, all patients were divided into an adult subgroup and a child subgroup.

###### Summary of 12 trials of NOTCH1/FBXW7 mutations included in this meta-analysis

  Source \[Reference\]       Country   Age     Protocols/Trials              Study groups   No. of patients   No. of events   
  -------------------------- --------- ------- ----------------------------- -------------- ----------------- --------------- ----
  Bonn et al (2013)          USA       Child   NHL-BFM                       Mut            74                na              62
                                                                             WT             42                na              28
  Clappier et al (2010)      Finland   Child   EORTC58951                    Mut            80                31              26
                                                                             WT             54                18              16
  Erbilgin et al (2010)      Turkey    Child   ALL-BFM protocols             Mut            20                15              16
                                                                             WT             67                39              54
  Fogelstrand et al (2014)   Sweden    Child   NOPHO ALL-1992 and ALL-2000   Mut            47                22              28
                                                                             WT             32                17              14
  Jenkinson et al (2013)     UK        Child   MRC UKALL 2003                Mut            101               37              36
                                                                             WT             57                16              15
  Myoung-Ja et al (2008)     Japan     Child   (JACLS) protocols ALL-97      Mut            22                22              21
                                                                             WT             33                26              23
  Abdelali et al (2010)      France    Adult   LALA-94 and GRAALL            Mut            159               25              21
                                                                             WT             73                4               4
  Baldus et al (2009)        Germany   Adult   GMALL 05/93 and 06/99         Mut            67                na              28
                                                                             WT             33                na              9
  Mansour et al (2009)       UK        Adult   UKALLXII/ECOGE2993 protocol   Mut            58                11              11
                                                                             WT             30                4               3
  Mansur et al (2012)        Brazil    Adult   BFM protocols                 Mut            62                36              25
                                                                             WT             48                23              23
  Trinquand et al (2013)     France    Adult   GRAALL-2003; GRAALL-2005      Mut            143               39              34
                                                                             WT             69                8               7
  Vlierberghe et al (2013)   USA       Adult   E2993 ECOG                    Mut            33                19              na
                                                                             WT             20                5               na

Abbreviations: WT, wild type; Mut, mutational status; OS: overall survival at 5 years; PFS: progression-free survival at 5 years. NA indicates not available.

5-year overall survival {#s2_3}
-----------------------

We analyzed the 5-year OS of all patients and found that two trials did not include this value. We eliminated those trials when performing the analysis. The pooled HR from the remaining trials was 0.61 (95% CI, 0.51--0.74; *P* \< 0.00001). HR of the child subgroup was 0.60 (95% CI, 0.42--0.87; *P* = 0.007) . HR of the adult subgroup was 0.62 (95% CI,0.50--0.77; *P* \< 0.00001). As the high degree of heterogeneity was performed, the HR of the adult subgroup was not sufficient (Figure [1A](#F1){ref-type="fig"}). We concluded that NOTCH1 and FBXW7 mutations were correlated with a better survival in T-ALL pediatric patients.

###### NOTCH1/FBXW7 mutations group

(**A**) Forest plot of hazard ratio (HR) of 5-year overall survival. (**B**) Forest plot of hazard ratio (HR) of 5-year progression-free survival. The estimation of the HR of each individual trial corresponds to the middle of squares and the horizontal line gives 95% confidence interval. The closed diamond shows overall HR with its 95% CI. HR \< 1 and 95% CI, excluding 1 indicate improved survival for the NOTCH1/FBXW7 mutations status arm compared with the wild-type NOTCH1/FBXW7 arm. O--E, observed minus estimated number of death. V, variance.
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5-year event-free survival {#s2_4}
--------------------------

One adult study did not include the relevant statistics for 5-year EFS. We eliminated that study. The pooled HR of the remaining studies was 0.57 (95% CI, 0.48--0.67; *P* \< 0.00001). In the child subgroup, HR was 0.59 (95% CI, 0.43--0.81; *P* = 0.00009). In the adult subgroup, HR was 0.56 (95% CI, 0.46--0.68; *P* \< 0.00001). Figure [1B](#F1){ref-type="fig"} shows that T-ALL patients who harbored NOTCH1 and FBXW7 mutations had a better prognosis than those who did not. Mutations in the child subgroup were not significantly different from those in the adult subgroup.

NOTCH1 mutation {#s2_5}
---------------

A total of 826 T-ALL patients from 16 trials \[[@R9]--[@R12], [@R16], [@R17], [@R21]--[@R27]\] had NOTCH1-type mutation. Details were shown in Table [2](#T2){ref-type="table"}. We divided the 826 patients into a child subgroup and an adult subgroup by the age. Six trials did not provide information about OS. In Callens et al. \[[@R28]\], patients' total survival periods were up to 4 years. Two trials did not provide patients EFS information. We eliminated those trials. The pooled HRs for 5-year OS and 5-year EFS from all the patients were, respectively, 0.76 (95% CI, 0.56--0.95; *P* = 0.02) and 0.63 (95% CI, 0.53--0.75; *P* \< 0.00001). For the child subgroups, relevant HR, 5-year OS, and 5-year EFS were 0.63 (95% CI, 0.42--0.94; *P* = 0.02) and 0.57 (95% CI, 0.45--0.72; *P* \< 0.00001). For the adult subgroups, relevant HR, 5-year OS, and 5-year EFS were 0.83 (95% CI, 0.62--1.10; *P* = 0.19) and 0.71 (95% CI, 0.55--0.92; *P* = 0.010). Figure [2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"} show that these outcomes are a more favorable survival indication for NOTCH1 mutation--positive patients than for NOTCH1 mutation--negative patients. When compared with adult patients, child patients had a better prognosis.

###### Summary of 14 trials of NOTCH1 mutations only included in this meta-analysis

  **Source \[Reference\]**   **Country**   **Age**   **Protocols/Trials**             **Study groups**   **No. of patients**   **No. of events**   
  -------------------------- ------------- --------- -------------------------------- ------------------ --------------------- ------------------- -----
  Bonn et al (2013)          USA           Child     NHL-BFM                          Mut                70                    na                  59
                                                                                      WT                 46                    na                  31
  Breit et al (2006)         German        Child     ALL-BFM 2000                     Mut                82                    na                  75
                                                                                      WT                 75                    na                  55
  Clappier et al (2010)      Finland       Child     EORTC58951                       Mut                80                    63                  58
                                                                                      WT                 54                    44                  38
  Erbilgin et al (2010)      Turkey        Child     ALL-BFM protocols                Mut                19                    14                  15
                                                                                      WT                 68                    41                  55
  Fogelstrand et al (2014)   Sweden        Child     NOPHO ALL-1992 ;1992; ALL-2000   Mut                45                    27                  26
                                                                                      WT                 34                    17                  16
  Gao et al (2014)           China         Child     BCH-2003 and CCLG-2008           Mut                39                    na                  36
                                                                                      WT                 53                    na                  34
  Huh et al (2013)           Korean        Child     NA                               Mut                9                     1                   1
                                                                                      WT                 7                     0                   0
  Kox et al (2010)           German        Child     ALL--BFM 2000                    Mut                150                   na                  112
                                                                                      WT                 151                   na                  130
  Myoung-Ja et al (2008)     Japan         Child     (JACLS) protocols ALL-97         Mut                17                    11                  17
                                                                                      WT                 38                    21                  23
  Zuurbier et al (2010)      German        Child     DCOG protocols                   Mut                42                    na                  32
                                                                                      WT                 29                    na                  16
  Zuurbier et al (2010)      German        Child     COALL protocols                  Mut                39                    na                  25
                                                                                      WT                 35                    na                  22
  Asnafi et al (2010)        France        Adult     LALA-94 ; GRAALL-2003            Mut                88                    50                  0
                                                                                      WT                 53                    26                  0
  Huh et al (2013)           Korean        Adult     NA                               Mut                7                     2                   2
                                                                                      WT                 6                     0                   0
  Mansour et al (2009)       UK            Adult     UKALLXII/ECOGE2993 protocol      Mut                53                    8                   8
                                                                                      WT                 35                    7                   6
  Mansur et al (2012)        Brazil        Adult     BFM protocols                    Mut                60                    32                  21
                                                                                      WT                 78                    38                  33

###### NOTCH1 mutations group

(**A**) Forest plot of hazard ratio of 5-year overall survival. (**B**) Forest plot of hazard ratio of 5-year progression-free survival.

![](oncotarget-08-66360-g002-1)

![](oncotarget-08-66360-g002-2)

FBXW7 mutations {#s2_6}
---------------

A total of 197 T-ALL patients in 9 trials \[[@R9], [@R11], [@R12], [@R16], [@R17], [@R21], [@R24], [@R25]\] harbored only the FBXW7 mutation. Details are shown in Table [3](#T3){ref-type="table"}. The 5-year EFS and OS for 10 reports analyzed for FBXW7 mutation status (7 reports for 5-year OS and 9 reports for 5-year EFS). The total-patients group (*n =* 431), had a 5-year OS of HR = 0.79 (FBXW7 mutations status vs wild-type FBXW7, *P* = 0.19). The total-patients group (*n =* 848) had a 5-year EFS of HR = 0.82 (FBXW7 mutations status vs wild-type FBXW7, *P* = 0.19). In the studies of children, the total-patients group (*n =* 220) had a 5-year OS of HR = 0.60 (FBXW7 mutations status vs wild-type FBXW7, *P* = 0.13). The total-patients group (*n =* 637) had a 5-year EFS of HR = 0.86 (FBXW7 mutations status vs wild-type FBXW7, *P* = 0.43). In the adult subgroup, the total-patients group (*n =* 211) had a 5-year OS of HR = 0.88 (FBXW7 mutations status vs wild-type FBXW7, *P* = 0.54). The total-patients group (*n =* 211) had a 5-year EFS of HR = 0.74 (FBXW7 mutations status vs wild-type FBXW7, *P* = 0.26). On the basis of the primary data demonstrated in Figure [3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}

###### Summary of nine trials of FBXW7 mutations included in this meta-analysis

  Source \[Reference\]       Country   Age     Protocols/Trials            Study groups   No. of patients   No. of events   
  -------------------------- --------- ------- --------------------------- -------------- ----------------- --------------- -----
  Bonn et al (2013)          USA       Child   NHL-BFM                     Mut            21                na              17
                                                                           WT             95                na              73
  Huh et al (2013)           Korea     Child   NA                          Mut            4                 1               1
                                                                           WT             12                0               0
  Kox et al (2010)           Germany   Child   ALL--BFM 2000 study         Mut            42                na              32
                                                                           WT             259               na              210
  Erbilgin et al (2010)      Turkey    Child   ALL-BFM protocols           Mut            7                 6               7
                                                                           WT             64                41              45
  Fogelstrand et al (2014)   Sweden    Child   NOPHO ALL-1992 ; ALL-2000   Mut            18                14              12
                                                                           WT             57                16              15
  Myoung-Ja et al (2008)     Japan     Child   (JACLS) protocols ALL-97    Mut            8                 8               5
                                                                           WT             47                40              22
  Huh et al (2013)           Korea     Adult   NA                          Mut            4                 1               1
                                                                           WT             9                 1               1
  Mansour et al (2009)       U K       Adult   UKALLXII/ECOGE2993          Mut            72                2               2
                                                                           WT             16                10              9
  Mansur et al (2012)        Brazil    Adult   BFM protocols               Mut            21                13              12
                                                                           WT             89                46              37

###### FBXW7 mutations group

(**A**) Forest plot of hazard ratio of 5-year overall survival. (**B**) Forest plot of hazard ratio of 5-year progression-free survival.
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We concluded that the FBXW7 mutation did not have a significant effect on the prognosis of the child patients and the adult patients.

In general, concurrent NOTCH1 and FBXW7 mutations were associated with a better patient survival than the NOTCH1 mutations.

Heterogeneity analysis and publication {#s2_7}
--------------------------------------

Heterogeneity, which correlated with the pooled OS and EFS HRs, was not distinct because the values were all less than 50%. Six funnel plots were almost symmetrical, indicating no obvious publication bias existed in our meta-analysis ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).

DISCUSSION {#s3}
==========

Ma et al. \[[@R29]\] carried out a literature-based meta-analysis that focused on the effect of NOTCH1 expression for the prognosis of T-ALL and found no beneficial effects on EFS in the NOTCH1 mutations subgroup. However, these original results are incomplete and the lack of a systematic review evaluation failed to give further insights on this issue. In our meta-analysis, we found that T-ALL patients with NOTCH1 mutations alone or in combination with FBXW7 have a better prognosis compared with those without FBXW7 mutations, without NOTCH1 mutations, or both, especially in the NOTCH1/FBXW7 subgroup. The statistically significant association with 5-year OS and EFS was detected in our study. We found that NOTCH1/FBXW7 mutations significantly increased the risk of long-term prognosis. Furthermore, the HR for 5-year EFS and OS in patients with NOTCH1 mutations were 0.63 (95% CI, 0.53 to 0.75) and 0.76 (95% CI, 0.60 to 0.95), and the HR for 5-year EFS and OS in patients with FBXW7 mutations were 0. 82 (95% CI, 0.60 to 1.11) and 0.79 (95% CI, 0.55 to 1.12). In all T-ALL patients in the 18 trials, we determined the incidence of activating mutations. The incidence in NOTCH1/FBXW7 genes was 60.60%. In addition, the number in NOTCH1 and FBXW7 genes was 51.11% and 22.38%. When we studied the child and adult subgroups separately, we found that the mutation event rate was a little higher in the adult subgroup.

Previous research showed the prognostic effect of the NOTCH1 mutation was linked to the ages of the patients \[[@R30]\]. Because child patients respond well to current therapy, the significance of molecular biomarkers can be decreased by the relatively good prognosis in the child subgroup, and no significant superiority of survival time was observed in patients without NOTCH1 mutations. We conducted the stratified analysis by age to determine the correlation between NOTCH1 and FBXW7 gene mutations and T-ALL prognosis. In the subgroup analysis according to age, for 5-year EFS, no significant associations were found among adult and child subgroups. Evidence indicates that children with mutations status have better 5-year OS than adults . However, both in child and in adult groups, the NOTCH1/FBXW7 mutations were correlated with a better 5-year EFS and 5-year OS. The presence of NOTCH1/FBXW7 mutations is a positive prognostic factor for T-ALL patient survival.

In the present meta-analysis, between-study heterogeneities for the overall data were absent in the six comparisons. Thus, the fixed-effect models were utilized. In the subgroup analyses, insignificant heterogeneities were also found in the relevant subgroups, increasing the stability and reliability of the results \[[@R31]\]. Several limitations should be addressed. First, the number of articles included was relatively small, especially for the FBXW7 group. Second, subgroup analyses with respect to treatment regimen, test methods, and other factors were not conducted in the present study because of the lack of relevant data in the primary literature. Third, some heterogeneity exists in the relation between mutations status and cancer prognosis. When the Calles article \[[@R28]\] was excluded, the heterogeneity disappeared. Despite the limitations, our meta-analysis indicated that T-ALL patients with concurrent NOTCH1 and FBXW7 mutations or a single NOTCH1 mutation had a significantly better survival than patients with wild-type FBXW7. So detecting mutation status by adopting molecular diagnosis could be an appropriate consideration. This method could be a beneficial therapeutic strategy.

MATERIALS AND METHODS {#s4}
=====================

Literature search strategy and study criterion {#s4_1}
----------------------------------------------

A sensitive search strategy was developed for all English language literature published before May 2014. The comprehensive search was performed by use of the electronic databases PubMed, EMBASE, and the Cochrane Library. The search terms were T-cell acute lymphoblastic leukemia or T-ALL, NOTCH1, and FBXW7. The search was limited to randomized controlled trials or clinical trials. Meta-analysis articles were not excluded because several original studies were often combined in meta-analysis articles.

The selection criteria were as follows:

\(a\) All T-ALL patients were diagnosed by immunophenotypic analyses according to World Health Organization classification. (b) NOTCH1 and FBXW7 mutation were identified by direct sequencing of polymerase chain reaction--amplified products. (c) Case studies, review articles, and studies involving fewer than three patients were excluded. (d) Randomized controlled trials compared immunotherapy versus control therapy and included children and adults. (e) Adequate survival information and patterns of failure data were needed.

Data extraction and quality control {#s4_2}
-----------------------------------

Two reviewers (RB. L and TZ. L) performed data extraction independently by use of standardized data extraction sheets. These data included study design, year of publication, population characteristics (country of patients and age), follow-up duration, trials, study groups, number of patients in each group and number of events in each group. Survival estimates were extracted directly from the text or deduced from the survival curve of the publication \[[@R32]\]. The principal summary measure was the hazard ratios (HRs), which could be extracted from the text or deduced from the original data. If the article did not provide the HRs for OS or event-free survival EFS, the Engauge Digitizer Version 4.1 software was used to distinguish the survival curves and calculate the HRs of OS and EFS. We extracted the *P* value of the log-rank test of the 5-year OS or the 5-year EFS.

To assign study quality, we examined the randomization procedure, estimation of sample size, allocation of concealment blinding of outcome assessor, loss to follow-up, dropout, and whether the intention-to-treat analysis was followed. The Jadad/Oxford quality scoring system was used to quantify study quality \[[@R33]\]. The study quality is shown in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. Any discrepancies in abstracting data were resolved by consensus.

Data synthesis and analysis {#s4_3}
---------------------------

Considering that NOTCH1 and FBXW7 belong to the same signaling pathway, the trials were classified into three subgroups, NOTCH1 alone; FBXW7 alone; and NOTCH1, FBXW7, or both, based on the mutations status of T-ALL patients. Subgroup analyses of the end events were performed by utilization of HR to assess the differences between the mutations arm and wild-type arm in each subgroup. Moreover, in each group, children and adults were analyzed. The main endpoint was OS, defined as the period from the randomization date to the date of death. Secondary endpoints were PFS, defined as the period from the randomization date to the date when disease progression (or death) was observed. Results regarding OS were expressed as HR with 95% CI, because it was the only summary statistic that allowed for both censoring and time to an event \[[@R34], [@R35]\]. The HRs and 95% CIs for the available data were calculated to identify potential correlations with overall survival in the two groups by use of the method reported by Tierney et al. \[[@R36]\]. An HR \< 1 means a lower rate of events in the mutations arm.

Statistical analysis was carried out by Review Manager Version 5.3 software provided by the Cochrane Collaboration. Heterogeneity was calculated by application of the Q-statistic and the I2 statistic. If the *Q* statistic *P* value \> 0.1, the HRs were pooled according to a fixed-effect model (Mantel-Haenszel). Otherwise, a random-effect model (DerSimonian and Laird) was selected. For I2, values of 25% to \< 50% were considered small, 50% to \< 75% were considered medium, and ≥ 75% were considered large \[[@R37]\].

Recognition of relevant researches {#s4_4}
----------------------------------

A total of 645 reports were retrieved when the electronic screening job was finished. After abstract review, 615 articles were excluded and 28 full-text articles remained. Afterward, 10 articles were eliminated for the following reasons: Six articles did not include NOTCH1 or FBXW7 mutation in their studies. Two articles did not analyze OS or EFS. Two articles were about the same trails in different publications. Eventually, 18 studies were eligible. The flow is shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}.
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